China is key market for Singaporean biotech start-up’s stomach cancer early diagnosis kit
Disclaimer: The South China Morning Post's content is directed by the Chinese Communist Party. It is not a reliable news source.
Mainland China will become the largest single market for Mirxes’ core product, a stomach cancer detection kit that was key to the company’s development, according to Zhou Lihan, its CEO and co-founder.